Investigative radiology
-
Investigative radiology · Jul 2003
Comparative StudyHigh-resolution three-dimensional contrast-enhanced blood oxygenation level-dependent magnetic resonance venography of brain tumors at 3 Tesla: first clinical experience and comparison with 1.5 Tesla.
To evaluate the clinical potential of high-resolution 3D contrast-enhanced blood oxygenation level-dependent MR-Venography (CE-MRV) for primary brain tumors and metastases at 3 Tesla (T) in comparison to 1.5 T. ⋯ Acquisition of CE-MRV data at 3 T enables spatial resolution to be increased within the same measurement time and with the same volume coverage compared with 1.5 T, thus providing more detailed information. The method may also show the potential to estimate oxygen supply of tumors, especially at high field strengths.
-
Investigative radiology · Jul 2003
Quantification of metabolic differences in the frontal brain of depressive patients and controls obtained by 1H-MRS at 3 Tesla.
This study compared metabolic differences in the frontal brain of depressed patients versus age- and sex-matched controls using proton magnetic resonance spectroscopy and absolute quantification of metabolites (NAA, Cr, Cho, mI) at 3 Tesla. ⋯ The authors demonstrate that absolute quantification of metabolite concentration is essential in properly identifying pathologic differences of brain metabolites in depression.
-
Investigative radiology · Jul 2003
Magnetic resonance imaging at 3.0 Tesla: challenges and advantages in clinical neurological imaging.
MR imaging at very high field (3.0 T) is a significant new clinical tool in the modern neuroradiological armamentarium. In this report, we summarize our 40-month experience in performing clinical neuroradiological examinations at 3.0 T and review the relevant technical issues. We report on these issues and, where appropriate, their solutions. ⋯ Fortunately solutions have been developed or are currently under development, by us and by others, for nearly all of these challenges. A short series of 1.5 T and 3.0 T patient images are also presented to illustrate the potential diagnostic benefits of scanning at higher field strengths. In summary, by paying appropriate attention to the discussed technical issues, high-quality neuro-imaging of patients is possible at 3.0 T.
-
Investigative radiology · Jun 2003
Visualization of normal and interrupted lymphatic drainage in dog legs with interstitial MR lymphography using an extracellular MR contrast agent, gadopentetate dimeglumine.
The capability of the interstitial magnetic resonance lymphography (MR-LG) using a widely available extracellular contrast agent, gadopentetate dimeglumine, for the visualization of normal and interrupted lymphatic drainage was tested in dog legs. ⋯ Although gadopentetate dimeglumine is not lymphotropic, the interstitial MR-LG using this T1-contrast agent appears to have potential for quick and sufficient mapping of the lymphatic drainage from the injection sites and for the characterization of interrupted lymph flow.
-
Investigative radiology · May 2003
Comparative StudyF-18 fluorodeoxyglucose positron-emission tomography in the diagnosis of tumor recurrence and metastases in the follow-up of patients with breast carcinoma: a comparison to conventional imaging.
To evaluate the role of F-18-fluorodeoxyglucose positron-emission tomography (F-18 FDG PET) in the follow-up of breast carcinoma in case of clinical suspicion of local recurrence or distant metastases and/or tumor marker increase in correlation to conventional imaging. ⋯ F-18 FDG PET demonstrates apparent advantages in the diagnosis of metastases in patients with breast carcinoma, compared with conventional imaging on a patient base. On a lesion base, significantly more lymph node and less bone metastases can be detected by using F-18 FDG PET compared with conventional imaging, including bone scintigraphy. In patients with clinical suspicion but negative tumor marker profile, too, F-18 FDG PET seems to be a reliable imaging tool for detection of tumor recurrence or metastases. Considering the high predictive value of F-18 FDG PET, tumor stage and therapeutic strategy will be reconsidered in several patients.